[Common variable immunodeficiency. A clinical approach].

Area of Science:

• Immunology
• Genetics

Context:

• Common variable immunodeficiency (CVID) affects approximately 1 in 50,000 newborns, presenting with diverse clinical symptoms.
• Diagnosis often occurs between ages 1-5 and 16-20, linked to impaired B lymphocyte antibody synthesis and class switching.
• Genetic defects are identified in only 10% of CVID cases, with the cause remaining unknown in most instances.

Purpose:

• To outline the characteristics, diagnosis, and management of Common Variable Immunodeficiency (CVID).
• To highlight the clinical manifestations, diagnostic criteria, and differential diagnoses for CVID.
• To emphasize the importance of immunoglobulin replacement therapy in mitigating CVID-related complications.

Summary:

• CVID is characterized by reduced immunoglobulin G, A, or M levels, leading to recurrent sinus-bronchial infections, autoimmunity, and increased cancer risk.
• Diagnosis involves suspecting CVID in patients with characteristic infections and laboratory findings, differentiating it from other antibody deficiencies.
• Molecular diagnosis requires ruling out mutations in genes such as TACI, ICOS, CD19, BAFF-R, and MSH5.

Impact:

• Early diagnosis and treatment, including immunoglobulin replacement therapy, can significantly reduce the risk of severe infections and pulmonary complications.
• Understanding CVID's pathophysiology aids in developing targeted therapies and improving patient outcomes.
• Further research into the genetic underpinnings of CVID is essential for identifying novel diagnostic and therapeutic strategies.